In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model

CRISPR-based gene editing technology represents a promising approach to deliver therapies for inherited disorders, including amyotrophic lateral sclerosis (ALS). Toxic gain-of-function superoxide dismutase 1 (SOD1) mutations are responsible for ~20% of familial ALS cases. Thus, current clinical stra...

Full description

Saved in:

Bibliographic Details
Published in:	Gene therapy Vol. 30; no. 5; pp. 443 - 454
Main Authors:	Chen, Yi A., Kankel, Mark W., Hana, Sam, Lau, Shukkwan Kelly, Zavodszky, Maria I., McKissick, Olivia, Mastrangelo, Nicole, Dion, Jessica, Wang, Bin, Ferretti, Daniel, Koske, David, Lehman, Sydney, Koszka, Kathryn, McLaughlin, Helen, Liu, Mei, Marshall, Eric, Fabian, Attila J., Cullen, Patrick, Marsh, Galina, Hamann, Stefan, Craft, Michael, Sebalusky, Jennifer, Arnold, H. Moore, Driscoll, Rachelle, Sheehy, Adam, Luo, Yi, Manca, Sonia, Carlile, Thomas, Sun, Chao, Sigrist, Kirsten, McCampbell, Alexander, Henderson, Christopher E., Lo, Shih-Ching
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-05-2023 Nature Publishing Group
Subjects:	42/41 42/44 631/61/201 631/61/2300 64/110 64/60 82/1 Action potential Amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis - genetics Amyotrophic Lateral Sclerosis - therapy Animals Atrophy Biomedical and Life Sciences Biomedicine Cell Biology CRISPR Denervation Disease Models, Animal Gene Editing Gene Expression Gene Therapy Genome editing Genomes Hereditary diseases Human Genetics Humans Life span Mice Mice, Transgenic Nanotechnology Neonates Neuromuscular junctions Spinal cord Superoxide dismutase Superoxide Dismutase - genetics Superoxide Dismutase - metabolism Superoxide Dismutase-1 - genetics Therapeutic targets
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	CRISPR-based gene editing technology represents a promising approach to deliver therapies for inherited disorders, including amyotrophic lateral sclerosis (ALS). Toxic gain-of-function superoxide dismutase 1 (SOD1) mutations are responsible for ~20% of familial ALS cases. Thus, current clinical strategies to treat SOD1-ALS are designed to lower SOD1 levels. Here, we utilized AAV-PHP.B variants to deliver CRISPR-Cas9 guide RNAs designed to disrupt the human SOD1 (huSOD1) transgene in SOD1 G93A mice. A one-time intracerebroventricular injection of AAV.PHP.B-huSOD1-sgRNA into neonatal H11 Cas9 SOD1 G93A mice caused robust and sustained mutant huSOD1 protein reduction in the cortex and spinal cord, and restored motor function. Neonatal treatment also reduced spinal motor neuron loss, denervation at neuromuscular junction (NMJ) and muscle atrophy, diminished axonal damage and preserved compound muscle action potential throughout the lifespan of treated mice. SOD1 G93A treated mice achieved significant disease-free survival, extending lifespan by more than 110 days. Importantly, a one-time intrathecal or intravenous injection of AAV.PHP.eB-huSOD1-sgRNA in adult H11 Cas9 SOD1 G93A mice, immediately before symptom onset, also extended lifespan by at least 170 days. We observed substantial protection against disease progression, demonstrating the utility of our CRISPR editing preclinical approach for target evaluation. Our approach uncovered key parameters (e.g., AAV capsid, Cas9 expression) that resulted in improved efficacy compared to similar approaches and can also serve to accelerate drug target validation.
ISSN:	0969-7128 1476-5462
DOI:	10.1038/s41434-022-00375-w